- Sanofi
- Abbott
- Bayer AG
- Aurobindo Pharma
- Bristol Myers Squibb
- Merck KGaA
- AstraZeneca
- Reddy’s Laboratories, Ltd.
- Novartis AG
- GlaxoSmithKline plc.
(Note: The list of the major players will be updated with the latest market scenario and trends)
Recent Development in Acute Sinusitis Market:
- In July 2022, Optinose unveiled the outcomes of their pre-planned analyses conducted as part of the ReOpen trial program, which assessed the effectiveness of XHANCE in treating patients with chronic sinusitis. XHANCE is a medication-device combination product that combines their proprietary Exhalation Delivery System (EDS), designed to deliver medication deep into nasal passages, with an anti-inflammatory drug.
- In August 2021, GlaxoSmithKline obtained approval from the Food and Drug Administration (FDA) for Nucala (mepolizumab) to treat Chronic Rhinosinusitis with nasal polyps.
Seasonal variation is the leading cause of Acute rhinitis, commonly seen during certain seasons, such as the fall and winter. These seasonal changes are bound to drive demand for over-the-counter (OTC) cold remedies, including antihistamines, decongestants, and cough syrups. After the COVID-19 pandemic, significant changes have been made, and it had played a vital role in increasing awareness of the importance of hygiene, such as handwashing and mask-wearing, causing a reduction in the transmission of common cold viruses, leading to a potential decrease in acute rhinitis cases. Moreover, this awareness could also drive demand for preventive products. Ongoing research and development have been increased after COVID-19 into antiviral drugs, vaccines, and other treatments for common cold viruses, which may result in new and more effective therapies. The public bodies are playing a crucial role in providing the funds for the R & D, which is again driving innovation and growth in the market.
However, the market growth faces particular challenges. Lack of effective treatment is a significant cause restraining the market growth. There is no cure for the common cold, and existing treatments primarily focus on symptom relief rather than addressing the underlying viral infection. The acute rhinitis market is saturated with OTC products, making it challenging for new entrants to gain market share. Competition can lead to price pressures and limit profit margins. Prolonged use of certain OTC medications, such as decongestant nasal sprays, can lead to tolerance and reduced effectiveness, discouraging the patients from using it and restraining the market growth.